Modular nanoarray vaccine for SARS-CoV-2

Zagorski, Karen; Pandey, Kabita; Rajesh, R.; Olwenyi, Omalla A.; Bade, Aditya N.; Acharya, Arpan; Johnston, Morgan; Filliaux, Shaun; Lyubchenko, Yuri L.; Byrareddy, Siddappa N.

doi:10.1016/j.nano.2022.102604

Cited by 4 publications

(3 citation statements)

References 50 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 195 , 196 More importantly, the nano formulation may be effective for all current mutant strains including the Omicron variant. 197 Recently, LNPs have been used to deliver the mRNA encoding SARS-CoV-2 S protein with incorporated ESCRT-I recruitment motif, enabling ESCRT-mediated secretion of viral spike protein VLPs from the cells. These VLPs displayed native, membrane-bound spike trimers on their surface, resulting in higher levels of neutralizing antibody titers 10 to 100-fold compared to soluble spike or commercial mRNA vaccines, and eliciting cellular immunity not achieved with mRNA vaccines alone.…”

Section: Nanotechnology’s Application In Infectious Diseasesmentioning

confidence: 99%

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Huang,

Guo,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Inflammation-associated diseases encompass a range of infectious diseases and non-infectious inflammatory diseases, which continuously pose one of the most serious threats to human health, attributed to factors such as the emergence of new pathogens, increasing drug resistance, changes in living environments and lifestyles, and the aging population. Despite rapid advancements in mechanistic research and drug development for these diseases, current treatments often have limited efficacy and notable side effects, necessitating the development of more effective and targeted anti-inflammatory therapies. In recent years, the rapid development of nanotechnology has provided crucial technological support for the prevention, treatment, and detection of inflammation-associated diseases. Various types of nanoparticles (NPs) play significant roles, serving as vaccine vehicles to enhance immunogenicity and as drug carriers to improve targeting and bioavailability. NPs can also directly combat pathogens and inflammation. In addition, nanotechnology has facilitated the development of biosensors for pathogen detection and imaging techniques for inflammatory diseases. This review categorizes and characterizes different types of NPs, summarizes their applications in the prevention, treatment, and detection of infectious and inflammatory diseases. It also discusses the challenges associated with clinical translation in this field and explores the latest developments and prospects. In conclusion, nanotechnology opens up new possibilities for the comprehensive management of infectious and inflammatory diseases.

show abstract

Section: Nanotechnology’s Application In Infectious Diseasesmentioning

confidence: 99%

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Huang,

Guo,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…The current mRNA and adenovirus-based vaccines have some concerns, including myocarditis, Guillain–Barré syndrome, and blood clotting disorders [ 15 , 16 , 17 , 18 ]. An epitope vaccine can target the immune response to specific neutralizing epitopes and can avoid immune-mediated disease enhancement [ 19 , 20 , 21 , 22 , 23 ]. Large numbers of peptide vaccine candidates have been described for HIV, influenza, COVID-19, and cancers, especially melanoma, breast, prostate, and lung cancer [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

MultiTEP-Based Vaccines Targeting SARS-CoV-2 Spike Protein IgG Epitopes Elicit Robust Binding Antibody Titers with Limited Virus-Neutralizing Activity

Antonyan,

Chilingaryan,

Zagorski

et al. 2024

Pathogens

Self Cite

View full text Add to dashboard Cite

Within the last two decades, SARS-CoV-2 was the third zoonotic severe acute respiratory betacoronavirus (sarbecovirus) to infect humans, following SARS and MERS. The disruptions caused by the pandemic underscore the need for a universal vaccine against respiratory betacoronaviruses. Our group previously developed the universal platform for vaccine development, MultiTEP, which has been utilized in this study to generate a range of SARS-CoV-2 epitope vaccine candidates. We prepared and characterized 18 vaccines incorporating small peptide fragments from SARS-CoV-2 Spike protein fused with the MultiTEP sequence using overlapping PCR. Wild-type mice were immunized intramuscularly with the immunogen formulated in AdvaxCpG adjuvant. Serum antibodies were detected by ELISA, surrogate neutralization, and pseudovirus neutralization assays. Finally, the most promising vaccine candidate was administered to three non-human primates. All vaccines generated high titers of spike-binding IgG antibodies. However, only three vaccines generated antibodies that blocked RBD binding to the ACE2 receptor in a surrogate virus neutralization assay. However, none of the vaccines induced antibodies able to neutralize pseudotype viruses, including after the administration of the lead vaccine to NHPs. MultiTEP-based COVID-19 vaccines elicited robust, IgG-binding responses against the Spike protein in mice and non-human primates, but these antibodies were not neutralizing, underscoring the need to refine this approach further.

show abstract

“…Moreover, AuNPs are among the most stable metal nanoparticles; they are highly biocompatible, easy to synthesize, and have numerous biomolecule functionalization abilities [15,16]. They have contributed significantly to the development of varied biosensors with highly improved analytical performance (low detection limits, sensitivity, response times), vaccine formulation [17][18][19][20][21][22], and the large-scale manufacturing of rapid tests [23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Updates on the Biofunctionalization of Gold Nanoparticles for the Rapid and Sensitive Multiplatform Diagnosis of SARS-CoV-2 Virus and Its Proteins: From Computational Models to Validation in Human Samples

Ionescu

2023

IJMS

View full text Add to dashboard Cite

Since the outbreak of the pandemic respiratory virus SARS-CoV-2 (COVID-19), academic communities and governments/private companies have used several detection techniques based on gold nanoparticles (AuNPs). In this emergency context, colloidal AuNPs are highly valuable easy-to-synthesize biocompatible materials that can be used for different functionalization strategies and rapid viral immunodiagnosis. In this review, the latest multidisciplinary developments in the bioconjugation of AuNPs for the detection of SARS-CoV-2 virus and its proteins in (spiked) real samples are discussed for the first time, with reference to the optimal parameters provided by three approaches: one theoretical, via computational prediction, and two experimental, using dry and wet chemistry based on single/multistep protocols. Overall, to achieve high specificity and low detection limits for the target viral biomolecules, optimal running buffers for bioreagent dilutions and nanostructure washes should be validated before conducting optical, electrochemical, and acoustic biosensing investigations. Indeed, there is plenty of room for improvement in using gold nanomaterials as stable platforms for ultrasensitive and simultaneous “in vitro” detection by the untrained public of the whole SARS-CoV-2 virus, its proteins, and specific developed IgA/IgM/IgG antibodies (Ab) in bodily fluids. Hence, the lateral flow assay (LFA) approach is a quick and judicious solution to combating the pandemic. In this context, the author classifies LFAs according to four generations to guide readers in the future development of multifunctional biosensing platforms. Undoubtedly, the LFA kit market will continue to improve, adapting researchers’ multidetection platforms for smartphones with easy-to-analyze results, and establishing user-friendly tools for more effective preventive and medical treatments.

show abstract

Modular nanoarray vaccine for SARS-CoV-2

Cited by 4 publications

References 50 publications

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

MultiTEP-Based Vaccines Targeting SARS-CoV-2 Spike Protein IgG Epitopes Elicit Robust Binding Antibody Titers with Limited Virus-Neutralizing Activity

Updates on the Biofunctionalization of Gold Nanoparticles for the Rapid and Sensitive Multiplatform Diagnosis of SARS-CoV-2 Virus and Its Proteins: From Computational Models to Validation in Human Samples

Contact Info

Product

Resources

About